Abstract
A series of novel 8-OMe ciprofloxacin (CPFX)-hydrazone/azole hybrids were designed, synthesized, and evaluated for their in vitro biological activities. Our results reveal that all of the hydrozone-containing hybrids (except for 7) show potency against Mycobacterium tuberculosis (MTB) H37Rv (minimum inhibitory concentration (MIC): <0.5 μM), which is better than the parent drug CPFX, and comparable to moxifloxacin and isoniazid, some of the tested Gram-positive strains (MIC: 0.06-4 μg/mL), and most Gram-negative strains (MIC: ≤0.03-4 μg/mL).
Keywords:
8-OMe ciprofloxacin; antibacterial; antimycobacterial; hybrids; synthesis.
MeSH terms
-
Animals
-
Anti-Bacterial Agents / chemical synthesis
-
Anti-Bacterial Agents / chemistry
-
Anti-Bacterial Agents / pharmacology
-
Antitubercular Agents / chemical synthesis
-
Antitubercular Agents / chemistry
-
Antitubercular Agents / pharmacology
-
Azoles / chemical synthesis
-
Azoles / chemistry
-
Azoles / pharmacology
-
Ciprofloxacin / analogs & derivatives
-
Ciprofloxacin / chemical synthesis
-
Ciprofloxacin / chemistry*
-
Ciprofloxacin / pharmacology
-
Humans
-
Hydrozoa / chemistry
-
Microbial Sensitivity Tests
-
Mycobacterium tuberculosis / drug effects*
-
Mycobacterium tuberculosis / pathogenicity
-
Tuberculosis / drug therapy*
-
Tuberculosis / microbiology
Substances
-
Anti-Bacterial Agents
-
Antitubercular Agents
-
Azoles
-
Ciprofloxacin